{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=87", "query": { "intervention": "SC", "page": 87 }, "page_size": 10 }, "pagination": { "page": 87, "page_size": 10, "total_count": 3868, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=88&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=86&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T21:41:18.085Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05315713", "title": "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma, Follicular Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab SC", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-05-10", "completion_date": "2023-07-19", "has_results": true, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 3, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Providence, Rhode Island", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05315713" }, { "nct_id": "NCT04339777", "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorders", "Autoimmune Lymphoproliferative", "Immune System Diseases", "Common Variable Immunodeficiency", "Primary T-cell Immunodeficiency Disorders" ], "interventions": [ { "name": "Busulfan test dose", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total body Irradiation", "type": "RADIATION" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Tacrolimus (Tacro)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Cyclophosphamide (Cytoxan)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "4 Years to 69 Years" }, "enrollment_count": 66, "start_date": "2020-09-22", "completion_date": "2032-11-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04339777" }, { "nct_id": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Soft Tissue Sarcoma (STS)", "Platinum-resistant Ovarian Cancer (PROC)", "Hepatocellular Carcinoma (HCC)", "Colorectal Cancer (CRC)", "HER2 Negative Breast Cancer", "Cutaneous Melanoma", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "GI-102 subcutaneous (SC)", "type": "DRUG" }, { "name": "GI-102", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "eribulin", "type": "DRUG" }, { "name": "trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2023-05-30", "completion_date": "2027-04-24", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05824975" }, { "nct_id": "NCT01476475", "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine /lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2011-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Paramount", "state": "California" }, { "city": "Larenceville", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476475" }, { "nct_id": "NCT00968357", "title": "Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "SCV-07", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciClone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2009-09", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 16, "location_summary": "Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00968357" }, { "nct_id": "NCT03112577", "title": "Study of REGN3500 and Dupilumab in Patients With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma, Allergic" ], "interventions": [ { "name": "REGN3500", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluticasone propionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 32, "start_date": "2017-06-15", "completion_date": "2019-12-09", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112577" }, { "nct_id": "NCT01773239", "title": "Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "TARA computer-based exercises", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Posit Science Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 16, "start_date": "2012-05", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773239" }, { "nct_id": "NCT01334177", "title": "TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "TLR8 agonist VTX-2337", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-05", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334177" }, { "nct_id": "NCT07441252", "title": "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overweight or Obesity and Elevated Liver Fat" ], "interventions": [ { "name": "Maridebart cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 180, "start_date": "2026-03-05", "completion_date": "2027-11-17", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 23, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07441252" }, { "nct_id": "NCT01059448", "title": "Safety and Efficacy of AMG 827 in Subjects With RA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "AMG 827", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 211, "start_date": "2010-06-03", "completion_date": "2011-04-05", "has_results": true, "last_update_posted_date": "2022-02-28", "last_synced_at": "2026-11-07T21:41:18.085Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Victorville", "state": "California" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059448" } ] }